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Background: The role of second-line therapy in gastric cancer patients mostly stemmed from clinical trials with
monochemotherapy carried out in Asian countries. Nevertheless, these results cannot be broadly generalized as
molecular studies suggested the existence of different sets of deregulated gene networks correlated with ethnicity.
In the present study, we investigated the activity and safety of FOLFIRI given as a second-line therapy in metastatic
gastric or gastro-esophageal junction cancer patients who experienced disease progression on or after first-line
docetaxel-containing chemotherapy.
Methods: Patients with histologically confirmed metastatic gastric cancer who failed docetaxel-containing first-line
therapy and who received FOLFIRI in second line were eligible for the study. Seventy patients treated at three
Italian cancer centers between 2005 and 2012 entered the study. Patients received every 2 weeks irinotecan
180 mg/m2 as 1 h infusion on day 1, folinic acid 100 mg/m2 intravenously days 1–2, and fluorouracil as a 400 mg/m2
bolus and then 600 mg/m2 continuous infusion over 22 hours days 1–2.
Results: We observed 1(1.4%) complete response, 15 (21.4%) partial response, for an overall response rate of 22.8%
(95% confidence interval (CI): 13.4-32.3). Stable disease was recorded in 21 (30%) patients. Median progression-free
survival and overall survival were 3.8 months (95% CI: 3.3-4.4) and 6.2 months (95% CI: 5.3-7.1), respectively. The
treatment was well tolerated, as the most common G3-4 toxicities were neutropenia (28.5%) and diarrhea (14.5%).
Conclusions: FOLFIRI appears an effective and safe treatment option for pretreated metastatic gastric cancer patients,
and deserves further investigation in randomized clinical trials.
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Gastric cancer and cancer of the gastro-oesophageal
junction (GEJ) are a significant global health problem,
representing the fourth most common cancer diagnosed
worldwide [1]. The prognosis for these patients remain
poor, as the majority of them are diagnosed with locally
advanced or metastatic disease with a median survival of
7–10 months [2].* Correspondence: maugeri.marcello@gmail.com
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distribution, and reproduction in any mediumSeveral randomized clinical trials demonstrated the
role of chemotherapy in the first-line setting, as different
regimens determined an improvement in survival and in
quality of life (QoL) compared with best supportive care
(BSC) alone [3-5]. More recently, a wave of randomized
clinical trials with superiority design was successfully
completed, and novel active drugs such as docetaxel [6],
S1 [7] and trastuzumab [8] changed the landscape of the
clinical management of gastric cancer. Other agents in-
cluding capecitabine [9], oxaliplatin [10] and irinotecan
[11] have proven antitumor activity, thus expanding the
spectrum of therapeutic options available in the first-line
setting. Even though novel active drugs and combinations
entered the therapeutic scenario, second-line treatmentCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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more, geographic distributions exist in chemotherapy ad-
ministration beyond first-line, being prevalently adopted
in Asian countries. Indeed, the rates of administration of
subsequent chemotherapy significantly differed among
phase III studies conducted in front-line, spanning from
14% in the UK REAL 2 study [9] to 75% in the Japanese
SPIRITS trial [7].
The clinical proof-of-concept for second-line chemo-
therapy stemmed from two recent randomized phase III
trials, demonstrating the superiority of second-line
monotherapy (docetaxel or irinotecan) over BSC [12,13].
Nevertheless, it is foreseeable that a widespread adoption
of second-line chemotherapy will further be limited by
multiple factors. Firstly, the non-Asian study was prema-
turely closed when only one-third of the preplanned
120 patients were enrolled [12]. As a result, evidence
supporting second-line chemotherapy in non-Asian
patients are still scattered being mostly extrapolated
from the Korean study. Secondly, the different biological
background of gastric cancer arising in Asian and Western
patients must be taken into account as a potential
confounding factor [14]. Finally, single-agent therapy may
result suboptimal, at least for patients with good perform-
ance status.
On this basis, we conducted a retrospective study in
order to evaluate the activity and safety of FOLFIRI
given as a second-line therapy in a cohort of docetaxel-
pretreated metastatic gastric cancer patients.
Methods
The study population was composed by patients with
metastatic gastric or GEJ cancer who experienced disease
progression on or after first-line docetaxel-containing
chemotherapy. Patients were treated at three Italian
cancer centers between 2005 and 2012. The majority of
patients was selected from the “Regina Elena” National
Cancer Institute, Rome. Medical records were reviewed in
order to obtain information on demography, treatment re-
ceived, safety and outcomes.
Patients with histologically confirmed, docetaxel-
pretreated metastatic gastric cancer who received
FOLFIRI in second line were eligible for the study.
Other eligibility criteria included Eastern Cooperative
Oncology Group performance status ≤2 (ECOG PS), aged
between 18 and 75 years, adequate bone marrow (absolute
neutrophil count ≥1500/μl, platelet count ≥100 000/μl),
renal (serum creatinine ≤1.5 mg/dl) and liver (serum
bilirubin ≤2 mg/dL) functions, normal cardiac func-
tion, absence of second primary tumor other than
non-melanoma skin cancer or in situ cervical carcin-
oma, no central nervous system involvement, no prior
radiotherapy in target lesions, and no concurrent un-
controlled medical illness.Patients received every 2 weeks irinotecan 180 mg/m2
as 1 h infusion on day 1, folinic acid 100 mg/m2 intra-
venously days 1–2, and fluorouracil as a 400 mg/m2
bolus and then 600 mg/m2 continuous infusion over
22 hours days 1–2. The dose of irinotecan was reduced
to 150 mg/m2 in patients older than 70 years. Chemo-
therapy was generally administered on an outpatient
basis for a maximum of 12 cycles. Treatment was con-
tinued until disease progression or unacceptable toxicity.
Toxicity was graded according to the National Cancer
Institute-Common Toxicity Criteria version 4.0 (NCI-
CTC v. 4.0). Tumor response was evaluated according to
the response evaluation criteria for solid tumors (RECIST
1.1). Progression-free survival (PFS) and overall survival
(OS) were calculated from the date of therapy initiation to
the date of disease progression, death from any cause or
last follow-up evaluation, respectively. PFS and OS were
analyzed according to the Kaplan-Meier method. The Cox
proportional hazards regression model was used for
univariate analysis of prognostic factors for survival.
All statistical analyses were performed using SPSS statis-
tical software version 20 (SPSS inc.,Chicago IL, USA).
The study was approved by the coordinating centre’s
Ethics Committee at the “Regina Elena” National Cancer
Institute, Rome, and was carried out according to the
principles of the Declaration of Helsinki. A written in-
formed consent was obtained from all patients.
Results
Patients characteristics
Seventy patients with a median age of 65 years (range,
32–75) were included in this study. Patients’ characteris-
tics are illustrated in Table 1. The primary tumor site
was stomach in 54 patients (77%) and the GEJ in 16 pa-
tients (23%). The histology subtype was diffuse, intestinal
and unknown in 33 (47%), 29 (41.5%), and 8 (11.5) pa-
tients, respectively. Primary tumor resection was carried
out in twenty-five patients (36%). The ECOG PS was 0,
1 and 2 in 10 (14.5%), 40 (57%) and 20 (28.5%) patients,
respectively. Fifty-three patients (76%) had two or more
metastatic sites. PFS during first-line chemotherapy was ≥
6 months in 42 patients (60%), and the chemotherapy-free
interval was > 3 months in 38 patients (54%). Among regi-
mens administered in the first-line setting, 25 patients
(36%) received docetaxel, oxaliplatin and capecitabine
[15], 20 patients (28.5%) received epirubicin, cisplatin
and docetaxel [16], 19 patients (27%) were treated with
epirubicin, oxaliplatin and docetaxel [17], and 6 patients
(8.5%) received cisplatin and docetaxel [18].
Efficacy
Response to treatment is illustrated in Table 2. Among
70 assessable patients, we observed 1(1.4%) complete re-
sponse (CR), 15 (21.4%) partial responses (PR), for an
Table 1 Patient characteristics
Characteristic No. of patients %
Patients evaluable 70 100
Age, years




Response to prior chemotherapy
Yes 44 63
No 26 37





















PFS under first-line chemotherapy
≥ 6 months 42 60
< 6 months 28 40
Chemotherapy-free interval
> 3 months 38 54
< 3 months 32 46
Abbreviations: ECOG PS Eastern Cooperative Oncology Group
Performance Status.
Table 2 Response rate in 70 patients
Responses No. of patients %
Complete response 1 1.4
Partial response 15 21.4
Stable disease 21 30
Progressive disease 33 47.2
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interval (CI): 13.4-32.3). Stable disease (SD) was recorded
in 21 (30%) patients, translating into a disease control rate
(DCR) of 52.8%. Median PFS was 3.8 months (95% CI:
3.3-4.4), and median OS was 6.2 months (95% CI: 5.3-7.1)
(Figure 1). In univariate analysis, the only significant
predictors of OS were ECOG PS (0–1 vs 2: 7.0 months[95% CI: 5.7-8.3] vs 5.0 months [95%CI: 2.4-7.6], P = 0.01;
HR 1.94 [95% CI: 1.13-3-33]) and PFS under first-line
chemotherapy (≥ 6 months vs < 6 months: 7.1 months
[95% CI: 6.2-8.0] vs 4.0 months [95% CI: 2.7-5.3], p = 0.04;
HR 1.67 [95% CI: 1.02-2.34]). We did not observe any
significant difference in efficacy nor in PFS and OS be-
tween patients who received fluoropyrimidine in the
first-line compared with patients who did not (ORR:
24.4% vs 20%; PFS 3.8 vs 4.0 months, P = 0.79; OS 6.2 vs
6.5 months, P = 0.61).
Toxicity
Toxicities are listed in Table 3. A total of 352 cycles of
FOLFIRI were analyzed in 70 patients, with a median of
6 cycles administered per patient (range, 2–12). The
most common G3-4 toxicities were neutropenia (28.5%)
and diarrhea (14.5%). Treatment discontinuation was ne-
cessary in 4 patients (5.7%). A 50% dose reduction was
required in 2 patients (2.8%) for recurrent G3 diarrhea,
whereas a 25% dose reduction was needed in 11 patients
(21.2%), mostly correlated with G3 diarrhea (7 patients).
Five patients required granulocyte colony-stimulating
factor (G-CSF) for G4 neutropenia.
Discussion
In the present study, we reported that the use of FOLFIRI
in the second-line setting in docetaxel-pretreated meta-
static gastric cancer is associated with an ORR of 22.8%
and a DCR of 52.8%. Median PFS and OS were 3.8 months
and 6.2 months, respectively. To our knowledge, this is
one of the largest series presented so far with second-line
chemotherapy combination in non-Asian patients.
In the second-line setting, only two recent studies
exploring the benefit of palliative chemotherapy were
presented in full text. The Arbeitsgemeinschaft
Internistische Onkologie (AIO) conducted in Germany
analyzed single agent irinotecan (250 mg/m2 every
3 weeks, increased to 350 mg/m2 after the first cycle
depending on toxicity) versus BSC [12]. Primary end-
point was OS. Even though the hazard ratio for death
was 0.48 (95% CI 0.25–0.92), results must be interpreted
with caution. Only 40 patients of the preplanned 120
entered the study, which closed prematurely due to
poor accrual. Regarding efficacy, no objective tumor
responses were documented, and disease stabilization
for at least 6 weeks was reported in 53% of patients.
Figure 1 Kaplan–Meier curves. (A) progression-free survival. (B) overall survival.
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Table 3 Main toxicity in 70 patients









aFour episodes of febrile neutropenia in 3 patients (4%).
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tive studies and indirect comparisons. In our study, patient
characteristics were similar, with the exception that in the
AIO study none of the patients allocated in the irinotecan
arm received docetaxel in first-line. However, even though
the DCR was similar (52.8% vs 53%), we reported an ORR
of 22.8%. Apparently, FOLFIRI compares favorably when
considering PFS (3.8 months vs 2.5 months) and OS
(6.2 months vs 4.0 months). Surprisingly, FOLFIRI seemed
to be better tolerated than irinotecan monotherapy (G3-4
diarrhea 14.4% vs 26%, neutropenic fever 4% vs 16%), prob-
ably because of the lower irinotecan cumulative dose and
the different schedule.
In the second phase III trial, 202 Korean patients were
randomized in a 2:1 fashion to receive either chemotherapy,
consisting in biweekly irinotecan 150 mg/m2 or docetaxel
60 mg/m2 every 3 weeks at the physician’s discretion, or
BSC [13]. Docetaxel-containing chemotherapy was adminis-
tered only in the 3% of patients. The intention to treat ana-
lysis showed an increase in OS with chemotherapy
(5.3 months vs 3.8 months) with a HR of 0.657 (95% CI:
0.485-0.891, P= 0.007). No differences were seen in correl-
ation with the type of chemotherapeutic agent, thus
complementing the results from the Japanese phase III
WJOG4007 study (reported only in abstract form) and from
an European, randomized, three-arm phase II study which
also evaluated a liposomal nanocarrier formulation of
irinotecan [19,20]. Even though these results have to be con-
sidered as a major step forward in the management of gas-
tric cancer, we believe they cannot be broadly generalized. It
is known that the topographic distribution (distal vs prox-
imal), pathological features (intestinal vs diffuse) and, even
more importantly, survival outcome differ between Asian
and Western patients [14,21,22]. Treatment pattern is one
of the factors proposed to explain such discrepancies, as
extensive D2 resection in early stage gastric cancer is rou-
tinely used in Asian countries. Nevertheless, a comparison
of surgical outcomes between patients treated at the
Memorial Sloan Kettering Cancer Center, where D2 re-
section is extensively carried out, and patients treated in
Korea revealed better disease-specific survival for thelatter group [23]. Therefore, it is foreseeable that under-
lying biological differences play a crucial role, and growing
evidence indicate that the molecular taxonomy of gastric
cancer is influenced by ethnic factors. MicroRNA expres-
sion profiling, which is emerging as an excellent classifier
in oncology, and next-generation sequencing studies
are beginning to unveil the existence of different sets of
deregulated gene networks potentially correlated with eth-
nicity [24-26]. Furthermore, the molecular analysis of the
ToGA trial revealed that HER2 positivity is associated
with the intestinal-type gastric cancer (32.5% intestinal vs
6.0% diffuse), the most common histology in Asia [8].
Overall, the different ethnicity-related molecular land-
scape of gastric cancer might reflect a different expression
of therapeutic targets and, in turn, sensitivity to anticancer
agents. Beyond tumor biology, also pharmacogenomic dif-
ferences should be taken into account. For instance, while
S1 is extensively used in front-line in Asia, its use in the
Western hemisphere was initially constrained by evidence
of more severe toxicity in Caucasian patients [27]. The dif-
ferent magnitude of toxic effects is thought to be corre-
lated with CYP2A6 gene polymorphisms, affecting the
conversion of S1 to fluorouracil. Indeed, in the phase III
FLAG study conducted in non-Asian countries S1 was
used at a lower dose compared to Japanese studies [28],
despite the higher body surface of Western patients.
Next, in the European FFCD-GERCOR-FNCLCC trial 416
patients were randomized to receive two different sequential
strategies in first- and second-line: epirubicin, cisplatin and
capecitabine in first-line and FOLFIRI in second-line vs the
reverse sequence [29]. The sequence with FOLFIRI in first-
line resulted superior for the primary endpoint (time to treat-
ment failure), a benefit deriving from the better tolerance
and the correlated lower rate of treatment discontinuation.
However, no firm conclusions can be drawn from this trial
having been only presented in abstract form to date.
Finally, a recent retrospective Turkish study reported data
from 97 docetaxel-pretreated patients who received FOLFIRI
in the second-line setting [30]. Investigators reported an
ORR of 26.8% and a DCR of 58.8%. However, it is worth
considering that 19 patients (19.5%) had locally recurrent
gastric cancer and 47 patients (48.5%) had only one meta-
static site. In our opinion, the rather heterogeneous study co-
hort along with the inclusion of a consistent fraction of
patients with lower tumor burden compared to those exa-
mined in our study led to an overestimation of the results,
as investigators reported a median OS of 10.5 months.
Conclusions
FOLFIRI appears an effective and safe treatment option
for pretreated metastatic gastric cancer patients. However,
second-line chemotherapy comparative trials are needed
to better define the role of FOLFIRI in gastric cancer
(e.g. versus monochemotherapy).
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